Revolutionizing translational potential in preclinical research

liver microscope flask graphics

Company profile

phoenixbio japan headquarter

PhoenixBio Co., Ltd. (Headquarters, Japan)

This is our largest site with 70+ employees and a continuous production of 100+ PXB-mice per week. In addition to in vivo study services for NAFLD/NASH, viral hepatitis, gene-based therapeutics, DMPK/toxicology, and custom transplantations, we also offer HBV study services at this location.


PhoenixBio USA Corporation (NYC Office)

This office is responsible for all non-Japanese clients. We complete project management, marketing, and sales from this office.

phoenixbio canada quarter

KMT Hepatech Inc., (Edmonton, Canada)

This is a production facility for PXB-mice and PXB-cells.

CMHL consortium logo

CMHL Consortium (Non-profitable Organization)

The Chimeric Mouse with a Humanized Liver (CMHL) Consortium was started by PhoenixBio to work with pharmaceutical industry and academic leaders to enhance applications and translational research using the PXB-mouse model. As of 2021, a total of 11 institutions, including eight pharmaceutical companies, are participating in the research.

Additional company information

Company Name PhoenixBio Co., Ltd.
Established March 4th, 2002
President and CEO Takashi Shimada
Fiscal term March
Capital 2,453 million yen (Mar.2023)
Headquarters 3-4-1 Kagamiyama, Higashi-Hiroshima City 739-0046 Japan
PhoenixBio USA Corporation 1120 Avenue of the Americas, Suite 1513, New York NY, 10036 USA
TEL +1-212-379-6411
FAX +1-212-379-6422
KMT Hepatech Inc.

2011-94 Street NW, Edmonton, Alberta, Canada, T6N1H1

CMHL Consortium LLC
Delaware, USA


Discover our products

Our Leadership

At PhoenixBio, our team strives to improve the global population’s quality of life and health through the application of our chimeric mouse model with a humanized liver. Our drive to improve the population’s health is central to the work we do to advance preclinical research and therapeutic development.

Board of Directors

Kenji Kuramoto: Chairman
Takashi Shimada: President & CEO
Yasuhiro Tamura: Executive Director of Administration
Chise Tateno-Mukaidani, Ph.D.: Executive Director of Research and Development
Yoshinori Fujii: External Director


Motoyasu Ueno: Full-time Auditor & Supervisory Board Member
Masatsugu Ueda, Ph.D.: Auditor & Supervisory Board Member
Hiromi Okano: External Auditor & Supervisory Board Member

Subsidiary Leadership

Yoshio Morikawa: President & CEO, PhoenixBio USA Corporation
Masakazu Kakuni, D.V.M., Ph.D.: President, KMT Hepatech Inc.

Get in Touch

Contact us to find out how the PhoenixBio team could help your drug discovery and development projects today.